Overview

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Status:
Completed

Trial end date:
2018-11-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if the combination of endocrine therapy and Palbociclib at a daily dose of 100 mg will result in a better response to therapy with fewer dose interruptions than the proposed dosing regimen of 125 mg daily for 21 days out of a 28 day cycle in combination with endocrine therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Canadian Cancer Trials Group

Collaborators:

Australia and New Zealand Breast Cancer Trials Group
Pfizer

Treatments:

Aromatase Inhibitors
Estrogens
Fulvestrant
Palbociclib
Tamoxifen